Comparative Effectiveness of Oral Anticoagulants and Home Time After Venous Thromboembolism in Frail and Non-Frail Older Adults

In this retrospective cohort of 18 066 Medicare fee-for-service beneficiaries ≥ 65 years with acute VTE (2015-2019), we compared apixaban, rivaroxaban, and warfarin using propensity score (PS) overlap weighting and intention-to-treat analyses across total, non-frail, and frail strata defined by a claims-based frailty index. After PS weighting (all SMDs < 0.10), apixaban versus warfarin was associated with a lower 1-year composite of recurrent VTE or death in the total population (189.1 versus 216.1 per 1000 PY; HR 0.86, 95% CI 0.77-0.96), with benefit evident in non-frail patients (114.5 versus 143.6; HR 0.78, 0.66-0.92) and attenuated in frail patients (330.9 versus 349.9; HR 0.93, 0.82-1.07). Recurrent VTE rates favored apixaban but were not statistically significant overall (40.5 versus 54.8; HR 0.86, 0.68-1.08). Major bleeding was lower with apixaban (19.4 versus 26.0; HR 0.73, 0.53-1.00). Home-time loss was reduced with apixaban compared with warfarin in the total population (mean 54.9 versus 67.0 days; RR 0.89, 0.83-0.96) and was directionally similar across both frailty strata. Rivaroxaban showed no clear advantage over warfarin for the composite (216.9 versus 216.1; HR 1.00, 0.90-1.11) or bleeding (HR 0.99, 0.73-1.32) and yielded greater home-time loss than apixaban (RR 1.08, 1.01-1.17). Overall, apixaban demonstrated the most favorable balance of effectiveness, safety, and patient-centered benefit, with patterns generally consistent across frailty levels.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Leech-derived molecules this paper discusses, each with a full profile in the ASH compound registry:

Узнайте, как это исследование связано с клинической практикой

More peer-reviewed studies in Клинические исследования.

• Leech Therapy for Knee Osteoarthritis — The Landmark RCT — Michalsen et al. (2003)
• Leech-Assisted Flap Salvage — Systematic Review of 277 Cases — Whitaker et al. (2012)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• HIRUDOTHERAPY IN PRESBYACUZIS PRAECOX IN CLEAN-UP WORKERS AFTER THE CHORNOBYL ACCIDENT DURING THE POST-CATASTROPHE YEARS — Zabolotnyi D, Mishchanchuk N (2019)
• Wound healing potential of bark paste of Pongamia pinnata along with hirudotherapy: A case report — Balasooriya D, Karunarathna C, Uluwaduge I (2021)
• AIF-1 and RNASET2 Play Complementary Roles in the Innate Immune Response of Medicinal Leech — Baranzini N et al. (2019)
• Study on the effect of medicinal leech therapy (Hirudo medicinalis) on full-thickness excisional wound healing in the animal model — Zakian A et al. (2022)
• [Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery--a literature review] — Knobloch K et al. (2007)
• The duration of rest and feeding greatly affects the re-breeding of ectoparasites: Hirudo verbana, Hirudo medicinalis and Hirudo orientalis — Aminov R, Frolov A, Aminova A (2022)
• Recombinant hirudin in clinical practice: focus on lepirudin — Greinacher A, Lubenow N (2001)

Browse all ASH-analysed research →